Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13D Filing: Alafi Capital Co LLC and Intra-Cellular Therapies Inc. (ITCI)

 

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Alafi Capital Company 3,953,270 0 3,953,270 0 3,953,270 7.2%
Christopher Alafi, Ph.D 1,327,594 3,953,270 1,327,594 3,953,270 5,280,864 9.7%
Moshe Alafi 0 3,953,270 0 3,953,270 3,953,270 7.2%

Page 1 of 12 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)

 

 

INTRA-CELLULAR THERAPIES, INC.

(Name of Issuer)

Common
Stock, par value $0.0001 per share

(Title of Class of Securities)

46116X 101

(CUSIP
Number)

Intra-Cellular Therapies, Inc.

430 East 29th Street

New York, NY 10016

Telephone: (646) 440-9333

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

October 2, 2017

(Date of
Event Which Requires Filing of This Statement)

 

 

If the filing
person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following
box.  ☐

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule
13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page
shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the
Act (however, see the Notes).

Follow Intra-Cellular Therapies Inc. (NASDAQ:ITCI)
Trade (NASDAQ:ITCI) Now!
Loading...